Antagonist antibodies against GDF-8 and uses therefor
AssigneePfizer Inc.
InventorsMichelle M. Mader, James R. Apgar, Kevin D. Parris
Life of this patent
Estimating the term…
Abstract
The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders.
Claims20
A method of increasing the mass or strength of a muscle of a mammal, comprising administering to a mammal a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds GDF-8, said antibody or fragment comprising:
- an antibody variable heavy (VH) region comprising first, second and third complementarity determining regions (CDR), wherein VH CDR1 comprises SEQ ID NO:10 or SEQ ID NO:20, VH CDR2 comprises SEQ ID NO:11 or SEQ ID NO:21, and VH CDR3 comprises SEQ ID NO:12;
- and
- an antibody variable light (VL) region comprising first, second and third complementarity determining regions (CDR), wherein VL CDR1 comprises SEQ ID NO:13, VL CDR2 comprises SEQ ID NO:14, and VL CDR3 comprises SEQ ID NO:15;
- wherein said VH region comprises leucine at the amino acid position corresponding to residue number 111 of SEQ ID NO:44 (Kabat position 108).
A method of treating a muscular disorder in a mammal characterized by diminished muscle mass or strength, comprising administering to a mammal in need of treatment for a muscular disorder characterized by diminished muscle mass or strength a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds GDF-8, said antibody or fragment comprising:
- an antibody variable heavy (VH) region comprising the first, second and third complementarity determining regions (CDR) from the VH region defined by the amino acid sequence of SEQ ID NO:44;
- and
- an antibody variable light (VL) region comprising the first, second and third complementarity determining regions (CDR) from the VL region defined by the amino acid sequence of SEQ ID NO:46;
- wherein said VH region comprises leucine at the amino acid position corresponding to residue number 111 of SEQ ID NO:44 (Kabat position 108).
Dependencies are inferred from the claim text.